Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The inspection was successfully completed
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Subscribe To Our Newsletter & Stay Updated